Research Summary

Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck. Dr.Kang joined UCSF from the Johns Hopkins University School of Medicine in Baltimore, MD where he was an Assistant Professor of Oncology, Otolaryngology - Head and Neck Surgery.

Dr.Kang completed his medical degree and public health degree at Yonsei University in Seoul, South Korea, then came to the US and had residency training at St.Luke's Roosevelt Hospital Center/Columbia University in New York City. He completed hematology and medical oncology fellowship at Emory University in Atlanta, GA.

Dr.Kang's research focus is development of clinical trials with novel therapeutic agents for patients with head and neck cancers. He has conducted/participated a number of clinical trials with immune checkpoint inhibitors and targeted therapy agents.


Yonsei University College of Sciences, Seoul, Korea, Premed Cert, 02/1998, Premedical Sciences
Yonsei University College of Medicine, Seoul, Korea, M.D., 02/2002, Medicine
Yonsei University Graduate School of Public Health, Seoul, Korea, M.P.H., 08/2007, Epidemiology and Statistics
St.Luke’s-Roosevelt Hospital Center/Columbia University College of P&S, New York, NY, Postdoctoral 06/2010 Internal Medicine Residency
Emory University School of Medicine, Atlanta, GA, Postdoctoral. 06/2013, Hematology/Oncology Fellowship

Honors & Awards

  • 2005
    Excellence in Public Health Service, Ministry of Health and Welfare, South Korea
  • 2012
    Travel Award, AACR/ASCO Methods in Clinical Research, Vail, CO

Selected Publications

  1. Soe MH, Chiang JM, Flavell RR, Khanafshar E, Mendoza L, Kang H, Liu C. Non-iodine Avid Disease is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer with Papillary Histology. J Clin Endocrinol Metab. 2022 May 12.  View on PubMed
  2. Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 02; 10(2).  View on PubMed
  3. Park JC, Ashok A, Liu C, Kang H. Real-World Experience of NTRK Fusion-Positive Thyroid Cancer. JCO Precis Oncol. 2022 02; 6:e2100442.  View on PubMed
  4. Min S, Kang H. What’s New in Molecular Targeted Therapies for Thyroid Cancer? Korean J Head Neck Oncol. 2021; 2(37):1-9.  View on PubMed
  5. Kim K, Kim CW, Shin A, Kang H, Jung SJ. Effect of chemotherapy and radiotherapy on cognitive impairment in colorectal cancer: evidence from Korean National Health Insurance Database Cohort. Epidemiol Health. 2021; 43:e2021093.  View on PubMed
  6. Lee RH, Kang H, Yom SS, Smogorzewska A, Johnson DE, Grandis JR. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes. Clin Cancer Res. 2021 Oct 01; 27(19):5168-5187.  View on PubMed
  7. Vellanki PJ, DeBoy EA, Bawadkji MM, Schuchter L, Rooper L, Mehra R, Kang H, Armanios M. Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations. JCO Precis Oncol. 2021; 5.  View on PubMed
  8. Wai KC, Kang H, Ha PK. Molecular Markers that Matter in Salivary Malignancy. Otolaryngol Clin North Am. 2021 Jun; 54(3):613-627.  View on PubMed
  9. Humtsoe JO, Kim HS, Leonard B, Ling S, Keam B, Marchionni L, Afsari B, Considine M, Favorov AV, Fertig EJ, Kang H, Ha PK. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer Res. 2021 02 15; 81(4):1001-1013.  View on PubMed
  10. Cui Z, Kang H, Grandis JR, Johnson DE. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. Mol Cancer Res. 2021 01; 19(1):14-24.  View on PubMed
  11. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 08 27; 383(9):825-835.  View on PubMed
  12. Park JC, Durbeck J, Boudadi K, Ho WJ, Kang H. The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma. Oral Oncol. 2020 09; 108:104935.  View on PubMed
  13. Jung K, Narwal M, Min SY, Keam B, Kang H. Squamous cell carcinoma of head and neck: what internists should know. Korean J Intern Med. 2020 09; 35(5):1031-1044.  View on PubMed
  14. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020 03; 31(3):412-421.  View on PubMed
  15. Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Head Neck. 2018 12; 40(12):E100-E106.  View on PubMed
  16. Park JC, Gourin CG, Kiess AP, Mehra R, Forastiere AA, Kang H. Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. Head Neck. 2018 12; 40(12):2612-2620.  View on PubMed
  17. Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. Oncologist. 2019 06; 24(6):791-797.  View on PubMed
  18. Kwatra SG, Ständer S, Kang H. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist. N Engl J Med. 2018 Oct 18; 379(16):1578-1579.  View on PubMed
  19. Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. Oncologist. 2019 02; 24(2):146-150.  View on PubMed
  20. Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. J Immunother Cancer. 2018 08 31; 6(1):84.  View on PubMed

Go to UCSF Profiles, powered by CTSI